12 Feb 2018 07:00
Hemogenyx Pharmaceuticals PlcÂ
("Hemogenyx" or the "Company")
Â
Director / PDMR Shareholding
Â
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces that it has been advised that on 9 February 2018 Adrian Beeston, Non-Executive Director, purchased 200,000 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 2.1p per share. Following this transaction Mr Beeston now has an interest in 6,331,969 Ordinary Shares, representing approximately 1.78 per cent. of the Company's issued share capital.
Â
The Notification of Dealing Form provided in accordance with the requirements of MAR in relation to the transactions listed above are set out below:
Â
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Â
1  | Details of the person discharging managerial responsibilities / person closely associated  | ||||
a)  | Name   | Adrian Beeston  | |||
2  | Reason for the notification  | ||||
a)  | Position/status   | Non-executive Director  | |||
b)  | Initial notification /Amendment   | Initial notification | |||
3  | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  | ||||
a)  | Name   | Hemogenyx Pharmaceuticals Plc | |||
b) Â | LEI Â Â | n/a | |||
4  | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  | ||||
a)  | Description of the financial instrument, type of instrument | Ordinary shares of £0.01 each | |||
Identification code | ISIN GB00BYX3WZ24 | ||||
 | |||||
b)  | Nature of the transaction   | Purchase of Ordinary Shares | |||
c) Â | Price(s) and volume(s) | Â | Â | Â | Â |
 | Price(s) | Volume(s) |  | ||
 | 2.1p | 200,000 |  | ||
 |  |  |  | ||
d) Â | Aggregated information | ||||
- Aggregated volume | Â N/A - single transaction | ||||
- Price | |||||
e)  | Date of the transaction   | 9 February 2018 | |||
f)  | Place of the transaction   | London Stock Exchange | |||
Â
Hemogenyx (HEMO)